Document is current
Any future updates will be listed below
-
Authors
Bhattoa, Harjit Pal https://orcid.org/0000-0002-4909-0065
Vasikaran, Samuel https://orcid.org/0000-0002-0831-3031
Trifonidi, Ioulia https://orcid.org/0000-0002-3999-8459
Kapoula, Georgia https://orcid.org/0000-0002-6714-0812
Lombardi, Giovanni https://orcid.org/0000-0002-8365-985X
Jørgensen, Niklas Rye https://orcid.org/0000-0001-9624-5210
Pikner, Richard https://orcid.org/0000-0002-0633-8876
Miura, Masakazu https://orcid.org/0000-0001-5685-3924
Chapurlat, Roland https://orcid.org/0000-0001-8214-6385
Hiligsmann, Mickael https://orcid.org/0000-0003-4274-9258
Haarhaus, Mathias https://orcid.org/0000-0001-8274-6356
Evenepoel, Pieter https://orcid.org/0000-0002-0797-4321
Jørgensen, Hanne Skou https://orcid.org/0000-0002-0881-2615
Herrmann, Markus https://orcid.org/0000-0002-3559-9899
Kaufman, Jean-Marc https://orcid.org/0000-0002-1400-6812
Clark, Patricia https://orcid.org/0000-0001-7981-5357
Tuzun, Şansın https://orcid.org/0000-0002-3300-2286
Al-Daghri, Nasser https://orcid.org/0000-0001-5472-1725
Silverman, Stuart https://orcid.org/0000-0002-5313-1018
Alokail, Majed S.
Ormarsdóttir, Sif
Yerro, María Concepción Prieto
Matijevic, Radmila https://orcid.org/0000-0002-4993-9399
Laslop, Andrea https://orcid.org/0009-0009-2707-3959
da Silva Rosa, Mario Miguel Coelho https://orcid.org/0000-0003-3158-2106
Zakraoui, Leith https://orcid.org/0000-0001-9276-5892
Burlet, Nansa
McCloskey, Eugene https://orcid.org/0000-0003-0177-8140
Harvey, Nicholas C. https://orcid.org/0000-0002-8194-2512
Radermecker, Régis P. https://orcid.org/0000-0002-2866-8171
Fusaro, Maria https://orcid.org/0000-0001-9478-4851
Torre, Carla https://orcid.org/0000-0002-5542-9993
Kanis, John A. https://orcid.org/0000-0002-3129-4326
Rizzoli, René https://orcid.org/0000-0002-1537-422X
Reginster, Jean-Yves https://orcid.org/0000-0001-6290-752X
Makris, Konstantinos https://orcid.org/0000-0002-7896-9028
Cavalier, Etienne https://orcid.org/0000-0003-0947-2226
-
Funding
Funding for this research was provided by:
University of Debrecen
- License Information
-
More Information
Article History
Received: 23 November 2024
Accepted: 3 February 2025
First Online: 28 March 2025
Declarations
:
: H.P.B.: No conflict of interest; S.V.: No conflict of interest; I.T.: No conflict of interest; G.K.: No conflict of interest; G.L.: Received speaker fee from SNIBE; N.R.J.: Received bone turnover marker assays free of charge for research from ROCHE, IDS and DiaSorin for research purposes; R.P.: No conflict of interest; M.M.: No conflict of interest; R.C.: Holds patents of 2 biomarkers of musculoskeletal diseases; M.Hiligsmann: Received research grants (paid to institution) from RADIUS HEALTH, and ANGELINI PHARMA, lecture fees from IBSA (paid to institution) and MYLAN PHARMACEUTICALS, and was grant advisor for PFIZER (paid to institution); M.Haarhaus: No conflict of interest; P.E.: Received research grants (paid to institution) from VIFOR CSL; H.S.J.: Received travel support from ABIOGEN PHARMA; M.Hermann: No conflict of interest; J-M.K.: No conflict of interest; P.C.: No conflict of interest; S.T.: No conflict of interest; N.A-D.: No conflict of interest; S.S.: No conflict of interest; M.S.A.: No conflict of interest; S.O.: No conflict of interest; M.C.P.Y.: No conflict of interest; R.M.: No conflict of interest; A.L.: No conflict of interest; M.M.C.d.S.R: No conflict of interest; L.Z.: No conflict of interest; N.B: No conflict of interest; E.M.: No conflict of interest; N.C.H: Received consultancy, lecture fees, honoraria, grant funding from ALLIANCE FOR BETTER BONE HEALTH, AMGEN, MSD, ELI LILLY, RADIUS HEALTH, SERVIER, SHIRE, UCB, CONSILIENT HEALTHCARE, KYOWA KIRIN, THERAMEX and INTERNIS PHARMA; R.P.R: No conflict of interest; M.F.: Received consultancy fees from ABIOGEN, AMGEN, VIFOR, OMEGA PHARMA; C.T.: No conflict of interest, the views expressed in this article are the personal views of the author and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies by which the author is employed or affiliated; J.A.K.: No conflict of interest; R.R.: No conflict of interest; JY.R.: Stakeholder of SarQoL® whereas he never received any financial or non-financial compensation for this activity, received consultancy fees from IBSA, PROMEDIUS, VIATRIS, REJUVENATE BIOMED, CELLTRION, AGNOVOS, THERAMEX and VERSANIS BIO, CHUGAI, member of the Speakers Bureau for IBSA, RADIUS HEALTH, VIATRIS, AGNOVOS and TRB CHEMEDICA, received research grants (through Institutions) from IBSA, RADIUS HEALTH, ECHOLIGHT, VIATRIS, THERAMEX and TRB CHEMEDICA; K.M.: Received free of charge reagents from ROCHE, SNIBE and IDS for research purposes; E.C.: Consultant for IDS, DIASORIN, FUJIREBIO, NITTOBO and MENARINI.
